Peter D. Meldrum
Vorstandsvorsitzender bei Myriad GmbH
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Walter A. Gilbert | M | 92 |
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 30 Jahre |
| S. Phanstiel | F | 65 | 15 Jahre | |
| David L. Clark | M | 70 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 19 Jahre |
| Heiner Dreismann | M | 69 | 14 Jahre | |
| Dale Muzzey | M | 44 | 10 Jahre | |
| Peter A. Friedli | M | 70 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
| Lode Debrabandere | M | 59 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
| Kimberly V. Rogers | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 20 Jahre |
| Tadashi Hirose | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
| Chad Bello | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 22 Jahre |
| Tracy H. Erkkila | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 23 Jahre |
| Brad VanWagenen | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 17 Jahre |
| Paul Robbins | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | - |
| Robert R. Becklin | M | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | 22 Jahre |
| Nathan Alan Smith | M | - |
Myriad GmbH
 Myriad GmbH Medical/Nursing ServicesHealth Services Part of Myriad Genetics, Inc., Myriad GmbH is a German company that provides health care services. The company is based in Munich, Germany. The CEOs of the company are Nathan Alan Smith, Peter D. Meldrum, Raymond Francot. | 6 Jahre |
| Raymond Francot | M | 61 |
Myriad GmbH
Myriad GmbH Medical/Nursing ServicesHealth Services Part of Myriad Genetics, Inc., Myriad GmbH is a German company that provides health care services. The company is based in Munich, Germany. The CEOs of the company are Nathan Alan Smith, Peter D. Meldrum, Raymond Francot. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| R. Riggsbee | M | 53 | 10 Jahre | |
| Mark Capone | M | 61 | 18 Jahre | |
| John Henderson | M | 79 | 16 Jahre | |
| Benjamin Jackson | M | 45 | - | |
| Mark H. Skolnick | M | 78 | - | |
| James S. Evans | M | 61 | 19 Jahre | |
| Brad D. Hardy | M | - |
University of Utah
| 5 Jahre |
| Lawrence C. Best | M | 75 | 11 Jahre | |
| R. Bruce Merrell | M | 78 |
University of Utah
| 6 Jahre |
| Alan C. Kay | M | 84 |
University of Utah
| 3 Jahre |
| Carl E. Brechtel | M | 74 |
University of Utah
| 5 Jahre |
| Alan C. Ashton | M | - |
University of Utah
| 8 Jahre |
| Wallace T. Boyack | M | 81 |
University of Utah
| 4 Jahre |
| Brent J. Giauque | M | - |
University of Utah
| 6 Jahre |
| Rebecca Chambers | F | 46 | 1 Jahre | |
| Lynn C. Miller | M | - |
University of Utah
| 1 Jahre |
| Randall W. Burt | M | - |
University of Utah
| 4 Jahre |
| James L. McCarrey | M | - |
University of Utah
| 6 Jahre |
| Kent H. Murdock | M | - |
University of Utah
| 7 Jahre |
| Kem C. Gardner | M | - |
University of Utah
| 7 Jahre |
| Gregory Goff | M | 67 |
University of Utah
| 7 Jahre |
| Christopher Aadnesen | M | 75 |
University of Utah
| 4 Jahre |
| Dennis Langer | M | 73 | 18 Jahre | |
| William A. Hockett | M | 67 | - | |
| Richard M. Marsh | M | 65 | 17 Jahre | |
| David E. Dangerfield | M | 83 |
University of Utah
| 5 Jahre |
| Gary F. Kennedy | M | 69 |
University of Utah
| 7 Jahre |
| William D. Kyle | M | 78 |
University of Utah
| 1 Jahre |
| Eugene Spiering | M | 70 |
University of Utah
| 6 Jahre |
| L. John Lewis | M | 74 |
University of Utah
| 4 Jahre |
| Fred W. Fairclough | M | 74 |
University of Utah
| 4 Jahre |
| Jon Methew Witkin | M | 70 |
University of Utah
| 4 Jahre |
| Tracy Stevenson | M | 73 |
University of Utah
| 4 Jahre |
| Richard J. Wenstrup | M | - | 2 Jahre | |
| Alexander Ford | M | - | 10 Jahre | |
| Glenn D. Warden | M | - |
University of Utah
| 3 Jahre |
| Randall J. Petersen | M | - |
University of Utah
| 4 Jahre |
| Ed T. Alter | M | - |
University of Utah
| 8 Jahre |
| Jeffrey W. Holmes | M | 70 |
University of Utah
| 4 Jahre |
| Tim Howells | M | - |
University of Utah
| 4 Jahre |
| Alan E. Nugent | M | 79 |
University of Utah
| 4 Jahre |
| David Aldous | M | 67 |
University of Utah
| 6 Jahre |
| Yvonne Campos | F | - |
University of Utah
| 1 Jahre |
| Russell Gentner | M | - |
University of Utah
| 4 Jahre |
| Terry O'Neill | F | 79 |
University of Utah
| 3 Jahre |
| David John Thomas | M | 80 |
University of Utah
| 4 Jahre |
| Andrew W. Smith | M | 72 |
University of Utah
| 4 Jahre |
| Craig Foster Pickett | M | - |
University of Utah
| 4 Jahre |
| Michael Ray Herrington | M | - |
University of Utah
| 4 Jahre |
| Gordon Kirkham | M | - |
University of Utah
| 4 Jahre |
| James E. Carter | M | - |
University of Utah
| 3 Jahre |
| Jane E. Judd | F | 77 |
University of Utah
| 4 Jahre |
| Scott Gleason | M | 45 | - | |
| James Earl Solomon | M | 73 |
University of Utah
| 4 Jahre |
| James H. Clark | M | 80 |
University of Utah
| 3 Jahre |
| Kirk Blosch | M | 69 |
University of Utah
| 4 Jahre |
| Terry C. Turner | M | 72 |
University of Utah
| 4 Jahre |
| Gary D. Kennedy | M | - |
University of Utah
| 3 Jahre |
| Michael T. Bebon | M | - |
University of Utah
| 2 Jahre |
| Michael Giordano | M | 77 |
University of Utah
| 2 Jahre |
| Larry Hendricks | M | 81 |
University of Utah
| 1 Jahre |
| Gregg B. Colton | M | 71 |
University of Utah
| 4 Jahre |
| Robert S. Attiyeh | M | 90 | 6 Jahre | |
| Mitchell T. Godfrey | M | 78 |
University of Utah
| 4 Jahre |
| Robert W. Cunningham | M | - |
University of Utah
| 4 Jahre |
| Edward B. Wilson | M | - |
University of Utah
| 4 Jahre |
| Thomas L. Harkness | M | 78 |
University of Utah
| 4 Jahre |
| Denny W. Nestripke | M | 76 |
University of Utah
| 4 Jahre |
| R. Matthew Shino | M | - |
University of Utah
| 6 Jahre |
| Howard S. Landa | M | 77 |
University of Utah
| 4 Jahre |
| Robert Harrison | M | 57 | 25 Jahre | |
| Adrian N. Hobden | M | 71 | - | |
| Charles D. Ebert | M | 70 |
University of Utah
| 4 Jahre |
| Steven C. Oldham | M | 73 |
University of Utah
| 4 Jahre |
| Larry Shaw | M | - |
University of Utah
| 4 Jahre |
| David M. Mock | M | 71 |
University of Utah
| 4 Jahre |
| Michael S. Anderson | M | 70 |
University of Utah
| 4 Jahre |
| Ronald G. Moffitt | M | - |
University of Utah
| 4 Jahre |
| Randall MacKey | M | 77 |
University of Utah
| 4 Jahre |
| Steve Atkinson | M | - |
University of Utah
| 2 Jahre |
| Robert Whitman | M | 71 |
University of Utah
| 4 Jahre |
| Michael M. Lloyd | M | - |
University of Utah
| 4 Jahre |
| F. Briton McConkie | M | - |
University of Utah
| 4 Jahre |
| Norman Cocke | M | - |
University of Utah
| 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 98 | 98,00% |
| Deutschland | 2 | 2,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Peter D. Meldrum
- Persönliches Netzwerk
